Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atossa Therapeutics ( (ATOS) ) just unveiled an announcement.
On April 16, 2026, Atossa Therapeutics reported that it had entered into a Settlement Agreement on April 13, 2026, with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve patent disputes over Endoxifen-related intellectual property, including challenges before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board. The parties agreed to seek termination of the PTAB proceedings, refrain from further participation or appeals if any proceeding is not fully terminated, and mutually covenant not to challenge specified Endoxifen-related patents and applications, while preserving Atossa’s right to develop and commercialize Z-endoxifen base in its core therapeutic areas.
The agreement also allocates certain Endoxifen-related fields and formulations among the parties, and Atossa expects its two key U.S. patents on “Methods for Making and Using Endoxifen” to remain issued and fully enforceable against other third parties following anticipated PTAB termination. Atossa believes the settlement reduces uncertainty surrounding its patent portfolio and supports continued execution of its strategic development plans for Z-endoxifen base, potentially strengthening its competitive and operational position in its targeted markets.
The most recent analyst rating on (ATOS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.
Spark’s Take on ATOS Stock
According to Spark, TipRanks’ AI Analyst, ATOS is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, increasing losses, and ongoing cash burn), with only the low-debt profile providing partial support. Technicals remain below key longer-term moving averages, and valuation is challenged by ongoing losses. Positive corporate developments (Nasdaq compliance and pipeline/regulatory progress) provide a meaningful but not decisive offset.
To see Spark’s full report on ATOS stock, click here.
More about Atossa Therapeutics
Atossa Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of Z-endoxifen base, targeting oncology, endocrine dysfunction disorders and muscular dystrophy-related diseases. The company’s strategy centers on leveraging its Endoxifen-related intellectual property to advance therapies in these core therapeutic areas and defend its position in related treatment fields.
Average Trading Volume: 127,243
Technical Sentiment Signal: Sell
Current Market Cap: $49.43M
Find detailed analytics on ATOS stock on TipRanks’ Stock Analysis page.